Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat

Molecular and Cellular Biochemistry

Volumn 320, Issue 1-2, 2009, Pages 149-162

  Balakumar, Pitchai ^a   Chakkarwar, Vishal Arvind ^a   Singh, Manjeet ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Benfotiamine; Diabetes; Fenofibrate; Nephropathy; Oxidative stress; Vascular endothelial dysfunction

Indexed keywords

BENFOTIAMINE; CHOLESTEROL; CREATININE; FENOFIBRATE; LISINOPRIL; TRIACYLGLYCEROL; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; GLOMERULAR DYSFUNCTION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PROTEINURIA; RAT; STREPTOZOCIN DIABETES; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD GLUCOSE; CHELATING AGENTS; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; LISINOPRIL; OXIDATIVE STRESS; PROTEINURIA; RATS; RATS, WISTAR; SUPEROXIDES; THIAMINE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VASCULAR DISEASES; VASODILATION;

RATTUS;

EID: 58049134293     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-008-9917-z     Document Type: Article

References (59)

1. Ritz E, Orth SR (1999) Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341:1127-1133. doi: 10.1056/NEJM199910073411506
2. De Vriese AS, Verbeuren TJ, De Voorde JV et al (2000) Endothelial dysfunction in diabetes. Br J Pharmacol 130:963-974. doi: 10.1038/ sj.bjp.0703393
3. Escandon JC, Cipolla M (2001) Diabetes and endothelial dysfunction: A clinical perspective. Endocr Rev 22:36-52. doi: 10.1210/er.22.1.36
4. Balakumar P, Koladiya RU, Ramasamy S et al (2008) Pharmacological interventions to prevent vascular endothelial dysfunction: Future directions. J Health Sci 54:1-16. doi: 10.1248/jhs.54.1
5. Heitzer T, Schlinzig T, Krohn K et al (2001) Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104:2673-2703. doi: 10.1161/ hc4601.099485
6. Laursen JB, Boesgaard S, Trautner S et al (2001) Endothelium-dependent vasorelaxation is inhibited by in vivo depletion of vascular thiol levels: Role of endothelial nitric oxide synthase. Free Radic Res 35:387-394. doi: 10.1080/10715760100300901
7. Ulker S, McKeown P, Bayraktutan U (2003) Vitamins reverse endothelial dysfunction through regulation of eNOS and NADPH oxidase activities. Hypertension 41:534-541. doi: 10.1161/01.HYP.0000057421.28533.37
8. Balakumar P, Kaur T, Singh M (2008) Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions. Toxicology 245:49-64. doi: 10.1016/j.tox.2007.12.011
9. Hink U, Li H, Mollnau H et al (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88:e14-e22
10. Kathryn CB, Chow WS, Victor HG et al (2002) Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 25:1055-1059. doi: 10.2337/diacare.25.6.1055
11. Thorand B, Baumert J, Chambless L et al (2006) Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 26:398-412. doi: 10.1161/01.ATV.0000198392.05307.aa
12. Nakagawa T, Sato W, Glushakova W et al (2007) Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 18:539-550. doi: 10.1681/ASN.2006050459
13. Prabhakar S, Starnes J, Shi S et al (2007) Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 18:2945-2952. doi: 10.1681/ASN.2006080895
14. Nakagami H, Kaneda Y, Ogihara T et al (2005) Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr Diabetes Rev 1:59-63. doi: 10.2174/1573399052952550
15. Song Y, Maanson JE, Tinker L et al (2007) Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women. Diabetes 56:1898-1904. doi: 10.2337/db07-0250
16. Balakumar P, Chakkarwar VA, Krishan P et al (2008) Vascular endothelial dysfunction: A tug of war in diabetic nephropathy? Biomed Pharmacother. doi: 10.1016/j.biopha.2008.08.008
17. Nakagami H, Morishita R, Yamamoto K et al (2001) Phosphorylation of p38 mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells. Diabetes 50:1472-1481. doi: 10.2337/diabetes.50.6.1472
18. Zhao HJ, Wang S, Cheng H et al (2006) Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 17:2664-2669. doi: 10.1681/ASN.2006070798
19. Futrakul N, Panichakul T, Sirisinha S et al (2004) Glomerular endothelial dysfunction in chronic kidney disease. Ren Fail 26:259-264. doi: 10.1081/JDI-120039524
20. Shah DI, Singh M (2006) Involvement of Rho-kinase in experimental vascular endothelial dysfunction. Mol Cell Biochem 283:191-199. doi: 10.1007/s11010-006-2679-6
21. Gojo A, Utsunomiya K, Taniguchi K et al (2007) The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 568:242-247. doi: 10.1016/ j.ejphar.2007.04.011
22. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820. doi: 10.1038/414813a
23. Stirban A, Negrean M, Stratmann B et al (2006) Benfotiamine prevents macro and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes 29:2064-2071. doi: 10.2337/dc06-0531
24. Babaei-Jadidi R, Karachalias N, Ahmed N et al (2003) Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52:2110-2120. doi: 10.2337/diabetes.52.8.2110
25. Marchetti V, Menghini R, Rizzal S et al (2006) Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/Foxo signaling. Diabetes 55:2231-2237. doi: 10.2337/db06-0369
26. Wang Z, Jiang T, Li J et al (2005) Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVB db/db mice with type 2 diabetes. Diabetes 54:2328-2335. doi: 10.2337/diabetes.54.8.2328
27. Molitch ME (2006) Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 1:1090-1099. doi: 10.2215/CJN.00780306
28. Balakumar P, Rose M, Ganti SS et al (2007) PPAR dual agonists: Are they opening pandora's box? Pharmacol Res 56:91-98. doi: 10.1016/ j.phrs.2007.03.002
29. Yang TL, Chen MF, Xia X et al (2004) Effect of fenofibrate on LDL-induced endothelial dysfunction in rats. Naunyn Schmiedebergs Arch Pharmacol 370:79-83
30. Yang TL, Chen MF, Xia X (2005) Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia. Eur J Clin Pharmacol 62:179-184. doi: 10.1007/s00228-005-0095-6
31. Chen LL, Zhang JY, Wang BP (2006) Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vascul Pharmacol 44:309-315. doi: 10.1016/ j.vph.2006.01.004
32. Trinder K, Hiraga Y, Nakamura N et al (1979) Determination of glucose in blood using glucose oxidase-peroxidase system and 8-hydroxyquinoline-p-anisidine. Chem Pharm Bull (Tokyo) 27:568-570
33. Allain CC, Poon LS, Chan CS et al (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20:470
34. Werner M, Gabrielson DJ, Eastman J (1981) Ultramicro determination of serum triglycerides by bioluminescent assay. Clin Chem 27:268-271
35. Jindal S, Singh S, Balakumar P (2008) Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. Int J Cardiol 128:383-391. doi: 10.1016/ j.ijcard.2007.05.031
36. Malczak HT, Buck RC (1997) Regeneration of endothelium in rat aorta after local freezing. A scanning electron microscopic study. Am J Pathol 86:133-148
37. Lai JCK, Tranfield EM, Walker DC et al (2003) Ultrastructural evidence of early endothelial damage in coronary arteries of rat cardiac allografts. J Heart Lung Transplant 22:993-1001. doi: 10.1016/ S1053-2498(02)01163-4
38. Greenwald I, Gross J (1924) The chemistry jaffe's reaction for creatinine. A red tautomer of creatinine picrate. Biol Chem 59:601-612
39. Fawcett JK, Scott E (1960) A rapid and precise method for the determination of urea. J Clin Pathol 13:156-159. doi: 10.1136/ jcp.13.2.156
40. Watanabe N, Kame S, Ohkubo A et al (1986) Urinary protein as measured with a pyrogallol red-molybdate complex manually and in a hitachi 726 automated analyzer. Clin Chem 32:1551-1554
41. Cha DR, Kang YS, Han SY et al (2004) Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J Endocrinol 183:183-194. doi: 10.1677/joe.1.05647
42. Tomohiro T, Kumai T, Sato T et al (2007) Hypertension aggravates glomerular dysfunction with oxidative stress in a rat model of diabetic nephropathy. Life Sci 80:1364-1372. doi: 10.1016/j.lfs.2006.11.054
43. Alderson NL, Chachich ME, Frizzel N et al (2004) Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia 47:1385-1395. doi: 10.1007/s00125-004-1474-8
44. Shah DI, Singh M (2006) Effect of fasudil on macrovascular disorder-induced endothelial dysfunction. Can J Physiol Pharmacol 84:835-845. doi: 10.1139/Y06-036
45. Gadau S, Emanueli C, Linthout S et al (2006) Benfotiamine accelerates the healing of ischemia diabetic limbs in mice through protein kinase B/ Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 49:405-420. doi: 10.1007/s00125-005-0103-5
46. De Sotomayor MA, Mingorance C, Andriantsitohaina R (2007) Fenofibrate improves age-related endothelial dysfunction in rat resistance arteries. Atherosclerosis 193:112-120. doi: 10.1016/j.atherosclerosis.2006.08.041
47. Cooke JP (2000) Does ADMA Cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20:2032-2037
48. Flanders KC, Burmester JK (2003) Medical applications of transforming growth factor-beta. Clin Med Res 1:13-20
49. Nicholas SB, Aguiniga E, Ren Y et al (2005) Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 67:1297-1307. doi: 10.1111/j.1523-1755.2005.00207.x
50. Paueksakon P, Revelo MP, Ma LJ et al (2002) Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int 61:2142-2148. doi: 10.1046/j.1523-1755.2002.00384.x
51. Hirano T, Kashiwazaki K, Moritomo Y et al (1997) Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res Clin Pract 36:11-18. doi: 10.1016/ S0168-8227(97)01384-3
52. Eddy AA (2002) Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 283:F209-F220
53. Taskinen MR (1990) Hyperlipidaemia in diabetes. Baillieres Clin Endocrinol Metab 4:743-775. doi: 10.1016/S0950-351X(05)80078-3
54. Sevak AR, Goyal RK (1996) Effects of chronic treatment with lisinopril on cardiovascular complications in streptozotocin diabetic and DOCA hypertensive rats. Pharmacol Res 34:201-209. doi: 10.1006/phrs.1996.0089
55. Trevisan R, Dodesini AR, Lepore G (2006) Lipids and renal disease. J Am Soc Nephrol 17:S145-S147. doi: 10.1681/ASN.2005121320
56. Vaziri ND, Sato T, Liang K (2003) Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis. Kidney Int 63:1756-1763. doi: 10.1046/j.1523-1755.2003.00911.x
57. Butler R, Morris AD, Struthers AD (2001) Lisinopril improves endothelial function in chronic cigarette smokers. Clin Sci 101:53-58. doi: 10.1042/ CS20010070
58. Amann B, Tinzmann R, Angelkort B (2003) ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes 26:2421-2425. doi: 10.2337/diacare.26.8.2421
59. Benigni A, Zoja C, Corna D et al (2003) Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 14:1816-1824. doi: 10.1097/01.ASN.0000074238.61967.B7